Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 27, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Photo Release -- Hemispherx Biopharma Posts Photographs of the Ampligen Facility in New Brunswick, New Jersey

NEW BRUNSWICK, N.J., Aug. 27, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing facility in New Brunswick, NJ. During the...
August 26, 2015 10:00 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma's Judgment Unanimously Affirmed Against Cato Capital

WILMINGTON, Del., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that on Friday the Third Circuit Court of Appeals upheld the...
August 26, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Photo Release -- Hemispherx Biopharma Hosts Stockholder Open House at Its Manufacturing and Research Development Center in New Jersey

NEW BRUNSWICK, N.J., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House at the company's newly renovated manufacturing and research...
August 24, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Enters Into Direct Supply Agreement With Gulf Coast Regional Blood Center to Supply Leukocytes to Manufacture Alferon N Injection(R)

PHILADELPHIA, Aug. 24, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced last week in its Quarterly Report on Form 10-Q that it has...
August 19, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Reminder Regarding Stockholder Open House at Manufacturing and Research Facility in New Jersey

PHILADELPHIA, Aug. 19, 2015 (GLOBE NEWSWIRE) -- As previously announced and provided in the proxy materials, the Management and the Board of Directors of Hemispherx Biopharma (NYSE MKT:HEB) will host...
August 17, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Extends Its Strategic Alliance With Armada Health Care for Alferon N Injection(R)

PHILADELPHIA, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that as the Company works toward the re-launch of Alferon N, it has...
August 13, 2015 09:00 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2015

PHILADELPHIA, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the six months ended June 30, 2015. The net loss (including non-cash effects)...
August 13, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Board Appoints New President

PHILADELPHIA, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the Board has appointed Thomas Equels as the new...
August 11, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Expands Its Collaboration With Emerge Health for the Commercialization of Alferon in Australia and New Zealand

PHILADELPHIA, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Emerge Health Pty Ltd....
August 10, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Enters Into an Agreement With myTomorrows for an Early Access Program for Rintatolimod in Europe

PHILADELPHIA, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Impatients, N.V., a...